Two Sigma Investments LP lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 155.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 302,376 shares of the biopharmaceutical company’s stock after buying an additional 184,202 shares during the quarter. Two Sigma Investments LP owned approximately 0.30% of Alnylam Pharmaceuticals worth $38,417,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $141,000. CENTRAL TRUST Co increased its position in shares of Alnylam Pharmaceuticals by 746.3% in the fourth quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 1,000 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $165,000. Segall Bryant & Hamill LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $235,000. Finally, American International Group Inc. bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $255,000. 92.44% of the stock is currently owned by hedge funds and other institutional investors.
In other news, VP Michael Mason sold 36,745 shares of the stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the sale, the vice president now owns 6,352 shares of the company’s stock, valued at $835,859.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $129.00, for a total value of $1,935,000.00. Following the sale, the director now directly owns 155,795 shares of the company’s stock, valued at approximately $20,097,555. The disclosure for this sale can be found here. In the last three months, insiders have sold 57,994 shares of company stock valued at $7,527,653. Insiders own 4.30% of the company’s stock.
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) opened at $144.16 on Wednesday. The firm has a market capitalization of $14,185.22, a P/E ratio of -26.65 and a beta of 2.67. Alnylam Pharmaceuticals, Inc. has a 52 week low of $46.90 and a 52 week high of $152.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). The company had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The business’s revenue for the quarter was up 116.6% compared to the same quarter last year. During the same period last year, the company posted ($1.32) EPS. sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.88 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/14/alnylam-pharmaceuticals-inc-alny-stake-raised-by-two-sigma-investments-lp.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.